Royalty Pharma plc Other Non-Current Assets
Royalty Pharma plc (RPRX) had Other Non-Current Assets of $62.96 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OtherAssetsNoncurrent · last filed 2026-08-05
- 2026-06-30: Other Assets, Noncurrent $62.96M.
- 2026-03-31: Other Assets, Noncurrent $76.85M.
- 2025-12-31: Other Assets, Noncurrent $79.29M.
- 2025-09-30: Other Assets, Noncurrent $86.58M.
| Period end | Other Assets, Noncurrent | Other Assets, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $62.96M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $76.85M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $79.29M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $86.58M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $85.49M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $36.71M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $33.53M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $42.79M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $27.55M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $4.49M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $6.52M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $20.21M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $29.41M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $28.03M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $29.63M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $30.61M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $33.41M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $3.87M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $4.14M 10-K · filed 2023-02-15 | |
| 2021-09-30 | $4.51M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $5.96M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $4.26M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $10.00M 10-K · filed 2022-02-15 | $23.16M 10-K · filed 2021-02-24 |
| 2020-09-30 | $4.89M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-12 | |
| 2019-12-31 | $45.63M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |